On March 9, 2021 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, reported the appointment of K. Peony Yu, M.D. as Chief Medical Officer (Press release, Apollomics, MAR 9, 2021, View Source [SID1234576259]). Dr. Yu will assume the role on March 16, 2021. Apollomics also announced that Sophie (Zhengjie) Sun has been named as Senior Vice President, Corporate Development and will be based in the Company’s China office. Both executives report to Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dr. Yu joins us with an incredible leadership and global drug development background that is a perfect fit for Apollomics, and we are thrilled to welcome her to our team," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "Peony’s extensive cross border experience includes managing teams in both the U.S. and China and overseeing multiple functions including clinical development, regulatory strategy and medical affairs. Peony will be instrumental in our efforts to advance our current assets and expand our development pipeline."

"Apollomics patient centric focus aligns with my priorities and I am excited to join the team. The Company’s precision medicine approach targeting specific mutations, amplifications and resistance mechanisms is technology that I believe can make a difference and bring transformative therapies to cancer patients. I look forward to contributing to this effort and advancing the clinical development programs globally," added K. Peony Yu, M.D.

Dr. Guo-Liang Yu, concluded, "Since inception, Apollomics has built numerous partnerships and we continuously explore options to broaden our portfolio. We are excited to welcome Sophie Sun who will be responsible for corporate strategy, business development, and strategic collaboration. Her diversified career covers three continents and her leadership in strategy, partnering, and commercialization will be a valuable resource as we continue our fight against cancer."

Peony Yu, M.D.

Dr. Yu spent 12 years at Fibrogen where she served in multiple roles of increasing responsibility culminating in her appointment as Chief Medical Officer in 2016. She brings leadership and expertise in design and execution of clinical development programs in all phases of development, including clinical and regulatory strategy, and interactions with global regulatory authorities.. Prior to joining Fibrogen, Dr. Yu was Vice President and Head of Clinical Research at Anesiva, Inc. (formerly known as Corgentech, Inc., (NASDAQ: ANSV)), where she was responsible for management of clinical research, statistics/data management, clinical operations, and medical affairs/medical information for all clinical programs. Dr. Yu received a Doctor of Medicine degree from the University of California, Davis. She completed her residency training at Stanford Medical School.

Sophie (Zhengjie) Sun, MBA

Sophie Sun joins Apollomics from Merck KGaA, where she was most recently Vice President & Managing Director, Innovation Hubs China. In this role, Ms. Sun oversaw Merck KGaA’s development partnerships in China for China and global markets. She was with Merck KGaA for twelve years holding multiple roles of increasing responsibility including participation in nine new product launches. Prior to Merck KGaA, Ms. Sun spent over eight years at marketing agencies Interpublic Group (IPG) and WPP, where she consulted for many Fortune 500 companies covering a wide range of industries. Ms. Sun received a Master’s degree from Remin University of China, and a Master of Business Administration from MIT Sloan School of Management.

On March 9, 2021 ChromaDex Corp. (NASDAQ: CDXC) reported to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT) (Press release, ChromaDex, MAR 9, 2021, View Source [SID1234576294]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be posted under the investor relations section of ChromaDex’s website at www.chromadex.com. A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings on March 16th and 17th. To register for the conference, please contact your Oppenheimer sales representative.

On March 9, 2021 Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that it is offering to sell shares of its common stock in an underwritten public offering (Press release, Jounce Therapeutics, MAR 9, 2021, View Source [SID1234576313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds of the offering are expected to be used to fund ongoing and planned clinical trials, including the INNATE trial for JTX-8064, to fund research and development to advance Jounce’s pipeline, and for working capital and other general corporate purposes. All of the shares in the offering are to be sold by Jounce. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jounce also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering on the same terms and conditions.

Cowen and Piper Sandler are acting as joint book-running managers for the offering.

The proposed offering is being made pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission ("SEC") on March 8, 2018 and declared effective by the SEC on May 1, 2018. The offering will be made only by means of the prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering can be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at 833-297-2926; or from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On March 9, 2021, Brickell Biotech, Inc. (the "Company"), reported that it entered into an At Market Issuance Sales Agreement (the "Agreement") with Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. as the Company’s sales agents (the "Agents") (Filing, 8-K, Vical, MAR 9, 2021, View Source [SID1234576329]). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company’s common stock having an aggregate offering price of up to $50,000,000 (the "Shares"). Any Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-254037) filed with the Securities and Exchange Commission (the "SEC") on March 9, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sales of the Shares, if any, will be made by means of ordinary brokers’ transactions on the Nasdaq Capital Market at market prices or as otherwise agreed by the Company and the Agents. Under the terms of the Agreement, the Company may also sell the Shares from time to time to an Agent as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the Shares to an Agent as principal would be pursuant to the terms of a separate placement notice between the Company and such Agent.

On March 9, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that it will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development (Press release, Infinity Pharmaceuticals, MAR 9, 2021, View Source [SID1234576348]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference call can be accessed in the Investors/Media section of Infinity’s website at www.infi.com. An archived version of the webcast will be available on Infinity’s website for 30 days.